This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Calle, R. A. et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat. Med. https://doi.org/10.1038/s41591-021-01489-1 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Greenhill, C. Phase IIa results for potential NAFLD therapy. Nat Rev Endocrinol 18, 2 (2022). https://doi.org/10.1038/s41574-021-00590-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-021-00590-2